When administered, this vaccine generates antibody against EGF which inhibits binding of EGF to EGF receptor.138 A phase II trial conducted with patients having IIIB/IV NSCLC did not show any survival benefit for the patients, however the patients who developed antibody response showed a better overall survival 139 (Table 1). Here, EGF is linked to non-small cell lung carcinoma.